Skip to main content
Article thumbnail
Location of Repository

Vaccine prevention of meningococcal disease, coming soon?

By Sarah L. Morley and Andrew J. Pollard


The past century has seen the use of a number of vaccines for prevention and control of meningococcal disease with varied success. The use of polysaccharide vaccines for the control of outbreaks of serogroup C infections in teenagers and young adults and epidemic serogroup A disease has been established for 30 years and an effective protein-polysaccharide conjugate vaccine against serogroup C was introduced into the Uk infant immunisation schedule in 2000. The next generation of these gycoconjugate vaccines will be on the shelf soon, eventually offering the prospect of eradication of serogroups A, C, Y and W135 through routine infant immunisation. Despite these exciting prospects, serogroup B meningococcal vaccines has been an elusive goal. Outer membrane vesicle vaccines for B disease are already used in some countries, and will likely be used more widely in the next few years, but efficacy for endemic disease in children has so far been disappointing. However, the innovation arising from the availability of the meningococcal genome sequence, public and scientific interest in the disease and recent pharmaceutical company investment in development of serogroup B vaccines may have started the countdown to the end of meningococcal infection in children.The full-text of this article is not currently available in ORA, but you may be able to access the article via the publisher copy link on this record page

Topics: Meningitis, Paediatrics, Vaccinology, protein-polysaccharide conjugate, meningococcal vaccines, serogroup B
Year: 2001
DOI identifier: 10.1016/S0264-410X(01)00410-8
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.